PPP1R12C and neurodevelopmental disorder: We demonstrated that both hPSC–AAVS1–EGFP and hPSC–AAVS1–EGFP-derived SN could be adapted to a high-content screening platform that can be applied to high-throughput phenotypic screening campaigns for drug discovery and chemogenomic approaches, i.e., robust biological screens and to elucidate unknown modes of action of neurodevelopmental disorders.